Sign in
Taking peopleNo phase

Looking at inflammation and walking ability in people with peripheral artery disease

Describes inflammation, general health and mobility in people with peripheral artery disease at heart clinics.

Key facts

Who runs it
Cardiology Research UBC
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Observing the Role of Inflammation in Peripheral Artery Disease and Its Impact on Heart and Mobility Health: PANACEA-O.
Status
Recruiting
People taking part
50 people, planned
Started
25 Sept 2025
Planned end
Jul 2026
Type of study
Observational
Record updated
30 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults in Canada with peripheral artery disease (narrowed leg arteries) who get leg pain when walking. People are seen in heart clinics and still live in the community. This is an observational study.

Age
19 years or older
Sex
All sexes
Disease stage
Stable leg pain when walking (Fontaine stage IIa) for at least 90 days. You can walk more than 200 m/656 feet/2 blocks without stopping.
Earlier treatment
No immunomodulating agent (a drug that changes the immune system) in the 90 days before screening. No artery-opening procedure for PAD in the 180 days before screening.
Biomarker or test result
Ankle-brachial-index (ABI) of 0.90 or below, or at least 50% narrowing of a leg artery (not the carotid) on a scan, or a past procedure to reopen leg arteries.

Main reasons for not taking part

  • Walking limited by conditions other than PAD
  • Planned leg bone surgery, other major surgery or artery-opening procedure
  • Heart attack, stroke, mini-stroke or hospital stay for unstable chest pain in the past 180 days
  • Heart failure NYHA class III-IV
  • Signs of critical limb ischemia, such as gangrene, pain at rest or wounds

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age >/= 19 years of age
  • Ability to provide informed consent before any trial-related activities
  • Symptomatic PAD with intermittent claudication corresponding to Fontaine stage IIa meeting all of the following:; Stable symptoms of PAD with intermittent claudication in Fontaine stage IIa (able to walk without stopping more than 200 m/656 feet/2 blocks) for at least 90 days prior to the day of screening based on patient interview; Ankle-brachial-index (ABI) equal to or below 0.90 (the leg with lowest index is chosen in case of bilateral disease) or ≥ 50% stenosis in peripheral artery (excluding carotid) documented by X-ray angiography, MR angiography, CT angiography or Doppler ultrasound, or a history of lower extremity revascularization

Who cannot take part

  • Current or previous treatment with any immunomodulating agent within 90 days prior to the day of screening
  • Planned orthopaedic surgery in the legs, or other major surgery known on the day of screening (surgery affecting walking ability)
  • Vascular revascularisation procedure for PAD of any kind 180 days prior to the day of screening
  • Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischemic attack within 180 days prior to the day of screening
  • Walking ability limited by conditions other than PAD
  • Heart failure presently classified as being in New York Heart Association (NYHA) class III-IV
  • Planned arterial revascularisation known on the day of screening
  • Signs/symptoms of critical limb ischemia (leg gangrene, rest pain, ischemic wounds, etc)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This registry aims to collect detailed information about people in Canada who have Peripheral Artery Disease (PAD) and are receiving care in heart clinics while still able to walk and live in the community. Researchers want to better understand what these patients are like at the start of their care and looking at their general health, levels of inflammation in their bodies, and how well they can move and function in daily life.

Read full original descriptionShow less

The results of this study will help healthcare providers better understand what PAD looks like in today's Canadian heart clinics. It will also help guide future research studies that focus on inflammation and PAD. The researchers believe that PAD patients can be routinely recruited from these clinics, and that most of these patients will have high levels of inflammation (shown by high blood CRP levels) and poor physical ability when they first join. The findings will show that there is a strong need to regularly check for PAD in heart clinics so that patients can be identified early and offered new treatments in the future and especially treatments that may help reduce inflammation.

The group in the trial

  • PAD

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Protocol Title Peripheral Arterial Disease and InflammatioN Study Assessing the Cardiovascular and Functional Effects - Observational Study: PANACEA-O
Plain-language title
Looking at inflammation and walking ability in people with peripheral artery diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
30 March 2026